Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myelitis, Transverse × Immunoglobulins, Intravenous × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms, Plasma Cell 3 Neoplasms 3 Myasthenia Gravis 3 Lymphoma 2 Leukemia 2 Infections 2 Urologic Neoplasms 1 Neuromyelitis Optica 1 Neuroblastoma 1 Myelitis, Transverse 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Limbic Encephalitis 1 Immunoglobulin Light-chain Amyloidosis 1 Hematologic Neoplasms 1 Epilepsy 1 Epilepsies, Partial 1 Drug Resistant Epilepsy 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Autoimmune Diseases of the Nervous System 1 Autoimmune Diseases 1

Interventions

eculizumab 3 ublituximab 1 Rituximab 1 Plasma Exchange 1 OM 89 1 N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide 1 Mitoxantrone 1 LFB-R603 1 Interferon beta-1a 1 Immunoglobulins, Intravenous 1 Blood Specimen Collection 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02398994 2016-07-20

STRIVE

Guy's and St Thomas' NHS Foundation Trust

Phase 3 Terminated

Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon ⚡